Literature DB >> 21772054

Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT.

M Anna Kowalska1, Sriram Krishnaswamy, Lubica Rauova, Li Zhai, Vincent Hayes, Karine Amirikian, Jeffrey D Esko, Daniel W Bougie, Richard H Aster, Douglas B Cines, Mortimer Poncz.   

Abstract

Heparin-induced thrombocytopenia (HIT) is caused by antibodies that recognize complexes between platelet factor 4 (PF4) and heparin or glycosaminoglycan side chains. These antibodies can lead to a limb- and life-threatening prothrombotic state. We now show that HIT antibodies are able to inhibit generation of activated protein C (aPC) by thrombin/thrombomodulin (IIa/TM) in the presence of PF4. Tetrameric PF4 potentiates aPC generation by formation of complexes with chondroitin sulfate (CS) on TM. Formation of these complexes occurs at a specific molar ratio of PF4 to glycosaminoglycan. This observation and the finding that the effect of heparin on aPC generation depends on the concentration of PF4 suggest similarity between PF4/CS complexes and those that bind HIT antibodies. HIT antibodies reduced the ability of PF4 to augment aPC formation. Cationic protamine sulfate, which forms similar complexes with heparin, also enhanced aPC generation, but its activity was not blocked by HIT antibodies. Our studies provide evidence that complexes formed between PF4 and TM's CS may play a physiologic role in potentiating aPC generation. Recognition of these complexes by HIT antibodies reverses the PF4-dependent enhancement in aPC generation and may contribute to the prothrombotic nature of HIT.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21772054      PMCID: PMC3172804          DOI: 10.1182/blood-2011-02-335208

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4.

Authors:  J S Suh; R H Aster; G P Visentin
Journal:  Blood       Date:  1998-02-01       Impact factor: 22.113

Review 2.  Thrombomodulin structure and function.

Authors:  J E Sadler
Journal:  Thromb Haemost       Date:  1997-07       Impact factor: 5.249

3.  Crystal structure of recombinant human platelet factor 4.

Authors:  X Zhang; L Chen; D P Bancroft; C K Lai; T E Maione
Journal:  Biochemistry       Date:  1994-07-12       Impact factor: 3.162

4.  Platelet factor 4 binds to glycanated forms of thrombomodulin and to protein C. A potential mechanism for enhancing generation of activated protein C.

Authors:  A Z Dudek; C A Pennell; T D Decker; T A Young; N S Key; A Slungaard
Journal:  J Biol Chem       Date:  1997-12-12       Impact factor: 5.157

5.  Role of the activation peptide domain in human factor X activation by the extrinsic Xase complex.

Authors:  R J Baugh; S Krishnaswamy
Journal:  J Biol Chem       Date:  1996-07-05       Impact factor: 5.157

6.  Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin.

Authors:  Don E Eslin; Chunyan Zhang; Kathleen J Samuels; Lubica Rauova; Li Zhai; Stefan Niewiarowski; Douglas B Cines; Mortimer Poncz; M Anna Kowalska
Journal:  Blood       Date:  2004-02-05       Impact factor: 22.113

7.  Modulation of glycosaminoglycan addition in naturally expressed and recombinant human thrombomodulin.

Authors:  J H Lin; K McLean; J Morser; T A Young; R M Wydro; W H Andrews; D R Light
Journal:  J Biol Chem       Date:  1994-10-07       Impact factor: 5.157

8.  Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia.

Authors:  L Ziporen; Z Q Li; K S Park; P Sabnekar; W Y Liu; G Arepally; Y Shoenfeld; T Kieber-Emmons; D B Cines; M Poncz
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

Review 9.  Enzymatic degradation of glycosaminoglycans.

Authors:  S Ernst; R Langer; C L Cooney; R Sasisekharan
Journal:  Crit Rev Biochem Mol Biol       Date:  1995       Impact factor: 8.250

10.  Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia.

Authors:  Lubica Rauova; Mortimer Poncz; Steven E McKenzie; Michael P Reilly; Gowthami Arepally; John W Weisel; Chandrasekaran Nagaswami; Douglas B Cines; Bruce S Sachais
Journal:  Blood       Date:  2004-08-10       Impact factor: 22.113

View more
  9 in total

Review 1.  Anticoagulating patients with high-risk acquired thrombophilias.

Authors:  Leslie Skeith
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally
Journal:  Blood       Date:  2017-04-17       Impact factor: 22.113

3.  Early Suspicion of Heparin-Induced Thrombocytopenia for Successful Free Flap Salvage: Reports of Two Cases.

Authors:  Turan Mehdizade; Osman Kelahmetoglu; Volkan Gurkan; Güven Çetin; Ethem Guneren
Journal:  J Hand Microsurg       Date:  2020-06-30

4.  Recognition of PF4-VWF complexes by heparin-induced thrombocytopenia antibodies contributes to thrombus propagation.

Authors:  Ian Johnston; Amrita Sarkar; Vincent Hayes; Gavin T Koma; Gowthami M Arepally; Junmei Chen; Dominic W Chung; José A López; Douglas B Cines; Lubica Rauova; Mortimer Poncz
Journal:  Blood       Date:  2020-04-09       Impact factor: 25.476

Review 5.  Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders.

Authors:  Douglas B Cines; Keith R McCrae; X Long Zheng; Bruce S Sachais; Eline T Luning Prak; Don L Siegel
Journal:  Blood       Date:  2012-09-10       Impact factor: 22.113

Review 6.  Heparin induced thrombocytopenia in critically ill: Diagnostic dilemmas and management conundrums.

Authors:  Sachin Gupta; Ravindranath Tiruvoipati; Cameron Green; John Botha; Huy Tran
Journal:  World J Crit Care Med       Date:  2015-08-04

7.  Fc-modified HIT-like monoclonal antibody as a novel treatment for sepsis.

Authors:  Kandace Gollomp; Amrita Sarkar; Sanjiv Harikumar; Steven H Seeholzer; Gowthami M Arepally; Kristin Hudock; Lubica Rauova; M Anna Kowalska; Mortimer Poncz
Journal:  Blood       Date:  2020-03-05       Impact factor: 25.476

Review 8.  COVID-19 versus HIT hypercoagulability.

Authors:  Theodore E Warkentin; Scott Kaatz
Journal:  Thromb Res       Date:  2020-08-10       Impact factor: 3.944

9.  Myocardial Infarction with Limb Arterial and Venous Thrombosis in a Patient with Enoxaparin-Induced Thrombocytopenia.

Authors:  Navdeep Singh; Sandeep Singh Lubana; Han-Mou Tsai
Journal:  Am J Case Rep       Date:  2020-05-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.